February 24, 2015 | SOURCE: REGEN BIOPHARMA, INC.

Regen BioPharma, Inc. Comments on dCellVax Cancer IDO-Targeting Technology in Relation to Bristol Myers Squibb-Flexus Biosciences, Inc. Announcement